Skip to main content
Caplight Logo









Osivax

Osivax

Private
LyonHealthcare & Life Scienceshttps://osivax.com/

Last Round

Grant

Aug 26, 2025

Total Funding Raised

$70.97M

Company Overview

Osivax is a biotechnology company that develops a transformative pipeline of universal vaccines designed to provide protection against viruses that mutate rapidly.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Clinical Trials, Drug Discovery, Advanced Materials

Business Model

B2G

Customer Profile

Government Contracts

AI Layer

Non-AI

Keywords

universal vaccineuniversal flu vaccineT-cell vaccineinfectious disease vaccineclinical stage biotechnanoparticle vaccinenext-gen vaccinevaccine developmentoligoDOMconserved protein vaccinepan-sarbecovirus vaccinerespiratory virus vaccinegovernment contractspharmaceutical partnerships

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Osivax Comparables

Compare Osivax with similar companies based on industry and business-model similarity.

Osivax comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Centivax, Inc.
87%
hVIVO plc
83%
FluGen, Inc.
81%

Osivax Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantAug 26, 2025
Series BMar 4, 2025
GrantDec 5, 2023
GrantJun 23, 2022
VC RoundJul 8, 2020
Grant
Jul 8, 2020

Key People

Founding team and executive leadership

Delphine Guyon-Gellin

Chief Business Development Officer and Chief Operating Officer

Executive Team

Osivax Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 26, 2025

    $19.5M grant from Public Health Emergency Medical Countermeasures Enterprise.

  • Jul 6, 2025

    Monthly visitors increased 267% MoM to 1.7K.

Osivax Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Osivax Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Osivax's valuation, stock price, and market status.

Firmographic Details

HeadquartersLyon
Employee Range62
Year Founded2017
Last FundingAug 26, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?